A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
Whether fluoxetine ( FX ) is effective in the treatment of  anxious depression  is still debated . In the present study , after one week of placebo ( single blind ) , 142 out patients affected by major depression with relevant anxiety and agitation were r and omly assigned ( double blind ) to either FX ( 20 mg/day ) ( n. 67 ) or amitriptyline ( AM ) ( daily dose : 115+/-39.2 mg ) ( n.75 ) for a period of 10 weeks . Between groups , the mean score of Hamilton Rating Scale for Depression ( HRSD ) was significantly different only after 3 weeks of treatment ( AM 14.7+/-5.7 vs FX 17.3+/-6.2 ( p = 0.02 ) , whereas at the end of the trial it was similar ( AM 8.15+/-6.9 ; FX 8.96+/-6.6 ) . At each visit , no significant difference between groups was found regarding the scores of the HRSD items " psychic anxiety " , " somatic anxiety " , " agitation " . Furthermore , the FIX treatment did not increase the scores of the items " suicide " , " psychic anxiety " , " somatic anxiety " , " agitation " and " insomnia " . These findings suggest that patients affected by major depression with anxiety and /or agitation were effectively and safely treated with FX without increasing risks
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .